BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND SSX1, MGC5162, 6756, ENSG00000126752, RP11-552E4_1, SSRC, MGC150425, Q16384
64296 results:

  • 1. Fibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer.
    Ye Y; Yang F; Gu Z; Li W; Yuan Y; Liu S; Zhou L; Han B; Zheng R; Cao Z
    J Transl Med; 2024 May; 22(1):474. PubMed ID: 38764020
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Index tumor location affected early biochemical recurrence after radical prostatectomy in patients with negative surgical margin: a retrospective study.
    Ogata Y; Akatsuka J; Endo Y; Mikami H; Yanagi M; Takeda H; Toyama Y; Yamamoto Y; Kimura G; Kondo Y
    BMC Urol; 2024 May; 24(1):108. PubMed ID: 38762458
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    GBD 2021 Risk Factors Collaborators
    Lancet; 2024 May; 403(10440):2162-2203. PubMed ID: 38762324
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
    Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
    Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
    Lin Y; Xu G; Li L; Xiang J; Zhai L
    Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. prostate intra-fraction motion recorded by transperineal ultrasound.
    Ballhausen H; Belka C; Li M
    Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. When to reinvite initially ineligible populations for targeted lung cancer screening?
    Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Determinants and Factors of Physical Activity After Oncology Treatments (DEFACTO) in Metropolitan France: Protocol of a Mixed Methods Study and Intervention.
    Aumaitre A; Gagnayre R; Foucaut AM
    JMIR Res Protoc; 2024 May; 13():e52274. PubMed ID: 38753415
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
    Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
    JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
    Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
    JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
    BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
    Ullah A; Jiao W; Shen B
    Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.
    Cheng J; Huo D; Zhang Z; Zhang J; Dong B; Liu Z; Zhou Z; Lu Y
    Med Oncol; 2024 May; 41(6):151. PubMed ID: 38743149
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer.
    Laurberg T; Witte DR; Gudbjörnsdottir S; Eliasson B; Bjerg L
    Sci Rep; 2024 May; 14(1):10956. PubMed ID: 38740921
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
    Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
    Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A bicentric retrospective study of the correlation of EAU BCR risk groups with
    Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
    Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
    Scilipoti P; Liedberg F; Garmo H; Wilberg Orrason A; Stattin P; Westerberg M
    Scand J Urol; 2024 May; 59():98-103. PubMed ID: 38738332
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Hematological and renal toxicity in mice after three cycles of high activity [
    Kristiansson A; Vilhelmsson Timmermand O; Altai M; Strand SE; Åkerström B; Örbom A
    Sci Rep; 2024 May; 14(1):10787. PubMed ID: 38734765
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
    Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on cancer Cell Lines.
    Albani M; Fassi EMA; Moretti RM; Garofalo M; Montagnani Marelli M; Roda G; Sgrignani J; Cavalli A; Grazioso G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731842
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3215.